Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

• Status: Recruiting
• Trial end date: 2025-11-06

Summary

This is a multicenter, randomized, open-label, Phase 3 study comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).

The study is anticipated to randomize approximately 381 subjects with RRMM. Approximately 254 subjects will be randomized to Treatment Arm A and approximately 127 subjects will be randomized to Treatment Arm B.

• Phase: Phase 3

Details

• Lead Sponsor: Celgene
• Treatments: BB 1101; Bortezomib; Daratumumab; Dexamethasone; Dexamethasone acetate; Elotuzumab; Ixazomib; Lenalidomide; Pomalidomide; Thalidomide